MRNA · 8-K · 20260731PR000147
Litigation Settlement Exposure
Moderna, Inc. · 2026-07-31 · Importance 75 · Surprise 60 · No source text
Moderna paid $950 million in July 2026 related to a litigation settlement announced in the first quarter of 2026. The company’s 2026 cost-of-sales outlook includes a $0.9 billion non-recurring litigation settlement charge. The payment contributed to the reduction in cash, cash equivalents and investments from $7.5 billion at March 31, 2026 to $6.9 billion at June 30, 2026. The settlement is also reflected in the company’s improved 2026 year-end cash projection of $4.7 billion to $5.2 billion, which excludes further credit-facility drawdowns.
Key facts
- The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -620.7% | The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. |
| cash | negative | realized | — | The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. |